These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22162541)

  • 1. Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients.
    Reitman ML; Dishy V; Moreau A; Denney WS; Liu C; Kraft WK; Mejia AV; Matson MA; Stoch SA; Wagner JA; Lai E
    J Clin Pharmacol; 2012 Sep; 52(9):1306-16. PubMed ID: 22162541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist.
    Guan XM; Metzger JM; Yang L; Raustad KA; Wang SP; Spann SK; Kosinski JA; Yu H; Shearman LP; Faidley TD; Palyha O; Kan Y; Kelly TM; Sebhat I; Lin LS; Dragovic J; Lyons KA; Craw S; Nargund RP; Marsh DJ; Strack AM; Reitman ML
    J Pharmacol Exp Ther; 2011 Feb; 336(2):356-64. PubMed ID: 21036912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Nonpeptide Agonist MK-5046 Functions As an Allosteric Agonist for the Bombesin Receptor Subtype-3.
    Ramos-Alvarez I; Iordanskaia T; Mantey SA; Jensen RT
    J Pharmacol Exp Ther; 2022 Aug; 382(2):66-78. PubMed ID: 35644465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
    Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J
    J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Selective Bombesin Receptor Subtype 3 Agonist Promotes Weight Loss in Male Diet-Induced-Obese Rats With Circadian Rhythm Change.
    Nio Y; Hotta N; Maruyama M; Hamagami K; Nagi T; Funata M; Sakamoto J; Nakakariya M; Amano N; Okawa T; Arikawa Y; Sasaki S; Okuda S; Kasai S; Habata Y; Nagisa Y
    Endocrinology; 2017 May; 158(5):1298-1313. PubMed ID: 28324017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects.
    Decochez K; Rippley RK; Miller JL; De Smet M; Yan KX; Matthijs Z; Riffel KA; Song H; Zhu H; Maynor HO; Tanaka W; Johnson-Levonas AO; Davies MJ; Gottesdiener KM; Keymeulen B; Wagner JA
    Drugs R D; 2006; 7(2):99-110. PubMed ID: 16542056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of novel imidazol-1-ylacetic acid derivatives as non-brain penetrant bombesin receptor subtype-3 (BRS-3) agonists.
    Kiyotsuka Y; Shimada K; Kobayashi S; Suzuki M; Akiu M; Asano M; Sogawa Y; Hara T; Konishi M; Abe-Ohya R; Izumi M; Nagai Y; Yoshida K; Abe Y; Takamori H; Takahashi H
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4205-10. PubMed ID: 27491709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization.
    Chobanian HR; Guo Y; Liu P; Lanza TJ; Chioda M; Chang L; Kelly TM; Kan Y; Palyha O; Guan XM; Marsh DJ; Metzger JM; Raustad K; Wang SP; Strack AM; Gorski JN; Miller R; Pang J; Lyons K; Dragovic J; Ning JG; Schafer WA; Welch CJ; Gong X; Gao YD; Hornak V; Reitman ML; Nargund RP; Lin LS
    Bioorg Med Chem; 2012 May; 20(9):2845-9. PubMed ID: 22494842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.
    Naik H; Vakilynejad M; Wu J; Viswanathan P; Dote N; Higuchi T; Leifke E
    J Clin Pharmacol; 2012 Jul; 52(7):1007-16. PubMed ID: 21610201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
    Addy C; Rothenberg P; Li S; Majumdar A; Agrawal N; Li H; Zhong L; Yuan J; Maes A; Dunbar S; Cote J; Rosko K; Van Dyck K; De Lepeleire I; de Hoon J; Van Hecken A; Depré M; Knops A; Gottesdiener K; Stoch A; Wagner J
    J Clin Pharmacol; 2008 Jun; 48(6):734-44. PubMed ID: 18508950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity.
    Guan XM; Chen H; Dobbelaar PH; Dong Y; Fong TM; Gagen K; Gorski J; He S; Howard AD; Jian T; Jiang M; Kan Y; Kelly TM; Kosinski J; Lin LS; Liu J; Marsh DJ; Metzger JM; Miller R; Nargund RP; Palyha O; Shearman L; Shen Z; Stearns R; Strack AM; Stribling S; Tang YS; Wang SP; White A; Yu H; Reitman ML
    Cell Metab; 2010 Feb; 11(2):101-12. PubMed ID: 20096642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology and pharmacology of bombesin receptor subtype-3.
    Majumdar ID; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2012 Feb; 19(1):3-7. PubMed ID: 22157398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of heterocyclic carboxylic acid isosteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
    Hadden M; Goodman A; Guo C; Guzzo PR; Henderson AJ; Pattamana K; Ruenz M; Sargent BJ; Swenson B; Yet L; Liu J; He S; Sebhat IK; Lin LS; Tamvakopoulos C; Peng Q; Kan Y; Palyha O; Kelly TM; Guan XM; Metzger JM; Reitman ML; Nargund RP
    Bioorg Med Chem Lett; 2010 May; 20(9):2912-5. PubMed ID: 20347296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel chiral diazepine derivatives as bombesin receptor subtype-3 (BRS-3) agonists incorporating an antedrug approach.
    Matsufuji T; Shimada K; Kobayashi S; Ichikawa M; Kawamura A; Fujimoto T; Arita T; Hara T; Konishi M; Abe-Ohya R; Izumi M; Sogawa Y; Nagai Y; Yoshida K; Abe Y; Kimura T; Takahashi H
    Bioorg Med Chem; 2015 Jan; 23(1):89-104. PubMed ID: 25497965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of a benzofuroquinolizine alpha 2-adrenoceptor antagonist.
    Gertz BJ; Vlasses PH; Rocci ML; Coker LD; Williams V; Bjornsson TD; Jones KH
    Clin Pharmacol Ther; 1989 Nov; 46(5):566-75. PubMed ID: 2573444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
    van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists.
    Guo C; Guzzo PR; Hadden M; Sargent BJ; Yet L; Kan Y; Palyha O; Kelly TM; Guan X; Rosko K; Gagen K; Metzger JM; Dragovic J; Lyons K; Lin LS; Nargund RP
    Bioorg Med Chem Lett; 2010 May; 20(9):2785-9. PubMed ID: 20371178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
    Liu J; He S; Jian T; Dobbelaar PH; Sebhat IK; Lin LS; Goodman A; Guo C; Guzzo PR; Hadden M; Henderson AJ; Pattamana K; Ruenz M; Sargent BJ; Swenson B; Yet L; Tamvakopoulos C; Peng Q; Pan J; Kan Y; Palyha O; Kelly TM; Guan XM; Howard AD; Marsh DJ; Metzger JM; Reitman ML; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2074-7. PubMed ID: 20219372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.